Oncotarget

Research Papers:

In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

Marta Michalska _, Susanne Schultze-Seemann, Lioudmila Bogatyreva, Dieter Hauschke, Ulrich Wetterauer and Philipp Wolf

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:22531-22542. https://doi.org/10.18632/oncotarget.8001

Metrics: PDF 1888 views  |   HTML 2575 views  |   ?  


Abstract

Marta Michalska1, Susanne Schultze-Seemann1, Lioudmila Bogatyreva2, Dieter Hauschke2, Ulrich Wetterauer1, Philipp Wolf1

1Department of Urology, Medical Center, University of Freiburg, Freiburg, Germany

2Institute for Medical Biometry and Statistics, Medical Center, University of Freiburg, Freiburg, Germany

Correspondence to:

Philipp Wolf, e-mail: [email protected]

Keywords: prostate cancer, PSMA, immunotoxin, docetaxel, chemotherapy

Received: November 26, 2015    Accepted: February 23, 2016    Published: March 9, 2016

ABSTRACT

Docetaxel (DOC) is used for the first-line treatment of castration resistant prostate cancer (CPRC). However, the therapeutic effects are limited, only about one half of patients respond to the therapy and severe side effects possibly lead to discontinuation of treatment. Therefore, actual research is focused on the development of new DOC-based combination treatments.

In this study we investigated the antitumor effects of a recombinant immunotoxin targeting the prostate specific membrane antigen (PSMA) in combination with DOC in vitro and in vivo. The immunotoxin consists of an anti-PSMA single chain antibody fragment (scFv) as binding and a truncated form of Pseudomonas aeruginosa Exotoxin A (PE40) as toxin domain. The immunotoxin induced apoptosis and specifically reduced the viability of androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer cells. A synergistic cytotoxic activity was observed in combination with DOC with IC50 values in the low picomolar or even femtomolar range. Moreover, combination treatment resulted in an enhanced antitumor activity in a C4-2 SCID mouse xenograft model. This highlights the immunotoxin as a promising therapeutic agent for a future DOC-based combination therapy of CPRC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8001